secwatch.observer — SEC 8-K summary
======================================

Issuer:     FEMASYS INC (FEMY)
CIK:        0001339005
Form:       8-K
Filed at:   2024-03-28T23:59:59+00:00
Accession:  0001140361-24-016160
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Femasys FY23 net loss $14.25M, sales down 11%; FemaSeed FDA clearance and positive trial data
--------------------------------------------------------------------------------

- Net loss $14.25M ($0.93/share) vs $11.39M ($0.96/share) in FY22; sales $1.07M (-11% YoY).
- FDA cleared FemaSeed for infertility; pivotal trial showed 24% pregnancy rate in severe male factor cohort.
- Cash $21.7M expected to fund operations into 2H 2025; convertible notes of $4.26M issued.
- Appointed Richard Spector as CCO and James Liu as CMO.
- FemBloc permanent birth control trial enrollment initiated.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1339005/000114036124016160/0001140361-24-016160-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1339005/000114036124016160/ef20025488_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-016160

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer